Vera Therapeutics

Gene Editing Technology

Also Clin2b IgA nephropathy; MAU868 Clin2 BK viremia in renal transplant, Clin0 BKV cystitis in HSCT

Vera Therapeutics late-stage biotech company focuses on developing treatments for serious immunological, inflammatory, and rare diseases such as nephropathy. They aim to not only treat symptoms, but target the source of disease through modulation of the immune system in order to transform the standard of care for these patients. This approach could not only halt disease, but has the potential for reversal of the disease. For example, through the inhibition of cytokines, B- cells are prevented from producing disease-causing antibodies that result in kidney disease. Overall, Vera is dedicated to addressing diseases that may be altered by the inhibition of autoantibody development, while keeping sustainability in mind.